TABLE 3.
Results from the oral bioavailability study of BNZ tabletsa
| Parameterb | Result for BNZ administration |
||||
|---|---|---|---|---|---|
| Immediate-release tablet |
i.v. | Extended-release tablet |
|||
| Adultc | Pediatric | ER-K4M | ER-K100M | ||
| Dose,d mg/kg | 42.2 (36,125–48,381) | 4.60 (4,324–4,882) | 3.07 (2,962–3,177) | 62.9 (58,194–67,794) | 68.6 (63,534–73,822) |
| AUC0–∞, μg/ml · h | 86.6 (62.4–110.8) | 3.6 (2.3–4.8) | 6.3 (5.0–7.6) | 153.9 (102.5–205.2) | 111.0 (77.3–144.7) |
| F, % | 99.8 (63.1–151.9) | 37.7 (25.9–51.0) | 118.9 (78.5–170.8) | 78.8 (36.8–139.4) | |
| RBA, % | 37.8 (21.6–61.4) | 119.2 (74.0–171.9) | 78.9 (59.5–102.8) | ||
a
Results are shown as means with 95% CIs in parentheses. n = 35 rabbits total (n = 7 in each group).
b
AUC0—∞, area under the concentration-time curve extrapolated to infinity; F, oral absolute bioavailability; RBA, oral relative bioavailability.
c
Used as the reference group in the RBA calculation.
d
Corrected dose by weight of the animals.